2022
Inflammatory pathways and cholangiocarcioma risk mechanisms and prevention
Cadamuro M, Strazzabosco M. Inflammatory pathways and cholangiocarcioma risk mechanisms and prevention. Advances In Cancer Research 2022, 156: 39-73. PMID: 35961707, PMCID: PMC10916841, DOI: 10.1016/bs.acr.2022.02.001.Peer-Reviewed Original ResearchConceptsDevelopment of cholangiocarcinomaNonalcoholic fatty liver diseaseAdequate therapeutic treatmentPrimary sclerosing cholangitisFatty liver diseasePro-inflammatory mechanismsMain risk factorsProdromal diseaseSclerosing cholangitisCaroli's diseaseMetabolic syndromeChronic cholangiopathiesLiver diseasePoor prognosisInflammatory pathwaysBiliary treeCCA developmentRisk factorsImmune responseImmunological responseTherapeutic targetCholangiocarcinomaFluke infestationRole of cellExtrahepatic areas
2020
Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective?
Torres M, Bodini G, Furnari M, Marabotto E, Zentilin P, Strazzabosco M, Giannini EG. Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? Cancers 2020, 12: 1422. PMID: 32486355, PMCID: PMC7352281, DOI: 10.3390/cancers12061422.Peer-Reviewed Original ResearchLiver diseaseHepatocellular carcinomaRisk factorsHCC surveillanceNAFLD patientsNon-alcoholic fatty liver diseasePrevalence of HCCFrequent primary liver cancerNon-alcoholic fatty liverNon-cirrhotic NAFLDNon-cirrhotic subjectsCause of cirrhosisTreatment of HBVChronic liver diseaseFatty liver diseasePrimary liver cancerCancer-related deathMain risk factorsGood clinical judgmentEarly HCC detectionDeaths/yearNew screening toolNAFLD epidemicHCV infectionLiver ultrasonography